๎๊ฒ์
๎๊ฒ์
๎
BioLine RX Ltd
BLRX๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
2.980USD
-0.070-2.30%
์ข
๊ฐย 05/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
12.54M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ BioLine RX Ltd ํ์ฌ
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BioLine RX Ltd ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ BLRX
ํ์ฌ ์ด๋ฆBioLine RX Ltd
์์ฅ์ผJan 30, 2007
CEOSerlin (Philip Adam)
์ง์ ์28
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃJan 30
์ฃผ์Modi'in Technology Park
๋์MODIIN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐIsrael
์ฐํธ ๋ฒํธ7177871
์ ํ97286429100
์น์ฌ์ดํธhttps://www.biolinerx.com/
์ข
๋ชฉ ์ฝ๋ BLRX
์์ฅ์ผJan 30, 2007
CEOSerlin (Philip Adam)
BioLine RX Ltd์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Apr 2
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Apr 2
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.84%
Intracoastal Capital, L.L.C.
0.07%
Rhumbline Advisers Ltd. Partnership
0.05%
BNP Paribas Securities Corp. North America
0.04%
๊ธฐํ
95.07%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.84%
Intracoastal Capital, L.L.C.
0.07%
Rhumbline Advisers Ltd. Partnership
0.05%
BNP Paribas Securities Corp. North America
0.04%
๊ธฐํ
95.07%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Corporation
4.00%
Hedge Fund
0.84%
Research Firm
0.12%
Investment Advisor
0.10%
๊ธฐํ
94.94%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
60
46.33K
1.06%
-104.55K
2025Q4
62
27.70K
3.92%
--
2025Q3
65
27.70K
4.05%
-38.51K
2025Q2
64
66.21K
2.82%
+56.76K
2025Q1
62
9.46K
4.78%
-168.28K
2024Q4
61
51.31K
6.91%
-11.13K
2024Q3
60
62.45K
12.93%
-43.93K
2024Q2
64
107.06K
9.39%
+72.30K
2024Q1
62
34.99K
9.95%
-145.17K
2023Q4
66
30.65K
11.57%
-4.56K
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Hong Seng Technology Ltd
170.73K
3.92%
--
--
Mar 16, 2025
Citadel Advisors LLC
36.65K
0.84%
+26.63K
+265.78%
Dec 31, 2025
Intracoastal Capital, L.L.C.
3.13K
0.07%
+3.13K
--
Mar 16, 2025
Rhumbline Advisers Ltd. Partnership
3.35K
0.08%
+283.00
+9.22%
Dec 31, 2025
BNP Paribas Securities Corp. North America
1.50K
0.03%
+1.50K
--
Dec 31, 2025
Wells Fargo Advisors
1.75K
0.04%
--
--
Dec 31, 2025
Citi Investment Research (US)
2.04K
0.05%
+2.04K
--
Dec 31, 2025
UBS Financial Services, Inc.
1.95K
0.04%
-4.44K
-69.45%
Dec 31, 2025
Nemes Rush Group, LLC.
250.00
0.01%
--
--
Dec 31, 2025
NewEdge Advisors, LLC
107.00
0%
--
--
Dec 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
Jan 17, 2025
Merger
40โ1
